Related Experiment Videos
Increased platelet CD36 constitutes a common marker in myeloproliferative disorders
V Thibert1, S Bellucci, M Cristofari
1INSERM U353 Hôpital Saint-Louis, Paris, France.
British Journal of Haematology
|November 1, 1995
Summary
Platelet CD36, a key protein in blood clotting, is significantly increased in myeloproliferative disorders (MPD). This finding suggests platelet CD36 could aid in diagnosing and monitoring MPD patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Platelet glycoproteins (GP) are crucial for hemostasis and thrombosis.
- Myeloproliferative disorders (MPD) involve abnormalities in blood cell production.
- CD36 (GP IV) is a platelet receptor for adhesive molecules.
Purpose of the Study:
- To investigate the distribution of major platelet glycoproteins in patients with MPD.
- To assess the diagnostic potential of platelet CD36 in MPD.
Main Methods:
- Studied 34 MPD patients (ET, PV, CML) and analyzed platelet membrane glycoproteins.
- Utilized radioimmunoassay and radiolabeled antibody binding (FA6-152) to quantify CD36.
- Measured GPIb and GPIIb-IIIa levels using radiolabeled antibody binding.
Main Results:
- Modifications in GPIb and GPIIb-IIIa were occasionally observed.
- Nearly all MPD patients showed a 2-3 fold increase in total CD36 content and surface expression.
- Abnormalities affected both internal and external CD36 pools.
- Increased CD36 did not correlate with thrombospondin binding in essential thrombocythaemia (ET) platelets.
Conclusions:
- Platelet CD36 levels are significantly elevated in MPD patients.
- Platelet CD36 may serve as a valuable biomarker for MPD diagnosis and follow-up.
- CD36 expression does not directly correlate with thrombospondin binding in ET.